43
Recommendation 12.8
➤ We suggest HSCT in patients with innate immune defects affecting
hematopoietic cell lineages and who manifest with recurrent,
persistent severe infections. (C-L)
Recommendation 12.9
➤ We recommend that any patient with IEI who receives definitive
treatment with HSCT, CTTI, or gene therapy receive life-long follow-
up by clinicians experienced in evaluating immune reconstitution and
monitoring for long-term complications of these procedures. (S-M)
Section 13. Precision Medicine in Inborn Errors of Immunity
Recommendation 13.1
➤ We recommend the use of targeted therapies to treat IEI based on
either an identified molecular defect or a clinical phenotype suggestive
of a defective immune function. (C-S; L-H)
